4. (Amended) The method of Claim 1, wherein said additive is selected from the group consisting of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, microcrystalline cellulose, starch, calcium carbonate and pharmaceutically acceptable carriers.

5. (Amended) The method of Claim 2, wherein the solid dosage is obtained by maceration of the compound *gugulipid*, starch and microcrystalline cellulose in proportions that provide a flowable powder.

6. (Amended) The method of Claim 2, wherein the solid dosage in the form of tablet is obtained by dissolving *gugulipid* with ethanol and adding starch and microcrystalline cellulose, evaporating the solvent, passing the material through 40 mesh size sieve to get the granules and compressing the granules to obtain tablets,

7. (Amended) The method of Claim 1, wherein the *gugulipid* is used for treating patients suffering from human memory dysfunctions caused by Alzheimer's disease or Korsakoff's disease, alone or in combination with other treatments.

8. (Amended) The method of Claim 1, wherein said dysfunction is an anticholinergic-induced amnesia.

9. (Amended) The method of Claim 8, wherein the *gugulipid* is administered at a dosage level equivalent to 40 mg/kg/day for 7 days.

10. (Amended) The method of Claim 8, wherein the *gugulipid* is administered as extract or solid dosage.

11. (Amended) The method of Claim 8, wherein the solid dosage is obtained by maceration of the compound *gugulipid*, starch and microcrystalline cellulose in proportions that provide a flowable powder.

12. (Amended) The method of Claim 8, wherein the solid dosage in the form of tablet is obtained by dissolving *gugulipid* with ethanol and adding starch and microcrystalline cellulose,